The inspection was conducted over four days, from 8 September to 11 September 2025, and concluded with zero form 483 observations, indicating full compliance with United States Food and Drug Administration (USFDA) regulatory requirements.
In an official statement, the company said it remains committed to upholding the highest standards of quality and regulatory compliance across its operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.
Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.
On consolidated basis, the company’s net profit (adjusted) stood at Rs 62.9 crore in Q1 FY26, down 24.8% year-on-year from Rs 83.5 crore in Q1 FY25. Revenue from operations rose 12.5% YoY to Rs 549.3 crore in Q1 FY26 from Rs 488.1 crore posted in Q1 FY25.
The counter shed 0.52% to Rs 989.95 on the BSE.